Abstract: The invention relates to an improved method of preparing oxymorphone or a salt thereof from oripavine. In particular, the invention relates to a method of preparing oxymorphone with a content of alpha-beta-unsaturated ketones (ABUK)<10 ppm, wherein the content of 8,14-dihydroxydihydromorphinone in the prepared oxymorphone is >10 ppm.

Abstract: The invention relates to an improved method of preparing oxymorphone or a salt thereof from oripavine. In particular, the invention relates to a method of preparing oxymorphone with a content of alpha-beta-unsaturated ketones (ABUK) <10 ppm, wherein the content of 8,14-dihydroxydihydromorphinone in the prepared oxymorphone is >10 ppm.

Abstract: A metering device activated by a user induced airstream for an inhalation of a medicinal substance. The device includes: a closure cap; a piston; a mouthpiece; and an annular chamber disposed upstream of the mouthpiece. A storage chamber stores the substance which can be moved out of the storage chamber when the closure cap is removed. A metering rod for removing the medicinal substance out of the storage chamber into an emptying-standby position. In the emptying-standby position, the metering chamber is closed by the piston. The piston is displaceable by airstream into an emptying-release position. In the emptying-release position, a metering chamber is released and the substance removed by the suction airstream. The metering device includes an outer cylinder which accommodates an inner cylinder.

Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.

Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.

Abstract: A metering device can be activated by a suction airflow of a user for inhaling a powdery substance, in particular of medicinal type, which is arranged in a supply chamber and can be brought out of there into an apparent discharge standby position by removing a mouthpiece sealing cap by a metering chamber of a metering rod. The metering device provides piston-extensible tabs for sealing off the metering chamber, particularly for the facilitated opening of the metering chamber.

Abstract: A dosing device can be activated by a vacuum air stream of a user for the inhalation of a powder substance, particularly medicine, which is arranged in a supply chamber and which can be brought out of the same into an open emptying-ready position by a dosing chamber of a dosing rod when the mouthpiece-closure cap is removed. In particular, in order to improve dispensing, the provision of two air paths, of which one serves to open and empty the dosing chamber, and/or the second air path penetrates directly into a ring chamber in order to mix with the air flow containing the substance.

Abstract: A dispersing unit for a powder inhaler comprises a mouthpiece with an annular channel for the delivery of a stream of particles. The annular channel has an axial inlet, and an axial outlet adjoined by an annular deflection chamber in which the axially incoming stream of particles is deflected to a predominantly radial direction of flow. The deflection chamber is adjoined in the axial direction by a rotation chamber with a circular peripheral wall and an axial outlet.

Abstract: Composition in the form of a tablet, comprising candesartan cilexetil and optionally further active agents and usual adjuncts, wherein the surface of at least the active agent candesartan cilexetil in this composition is provided with a coating, made from a compound or a mixture of compounds selected from tri-(C1-C6)alkyl citrate, di-(C1-C6)alkyl phthalate, di-(C1-C6)alkyl sebacate and polydimethysiloxanes and methods for production thereof.

Abstract: Granules for controlled release of Tamsulosin, the granules including Tamsulosin and a carrier matrix. The carrier matrix includes a) 2 to 25% by weight of an alginate and b) 30 to 70% by weight of a macromolecular substance selected from the group consisting of: methacrylic acid/ethyl acrylate 1:1 copolymer, methacrylic acid/methyl methacrylate 1:1 or 1:2 copolymers, aminoalkyl methacrylate copolymer, vinyl acetate/crotonic acid copolymer, polyvinyl acetate phthalate, ethylene-vinyl acetate, cellulose acetate phthalate, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, carrageenan, crosslinked chitosan, polyethylene-vinyl acetate, poly-L-lactic acid, xanthan gum, polyvinyl acetate and mixtures thereof. The carrier matrix further includes 10 to 50% by weight of a hydrophobic substance selected from the group consisting of: glycerol behenate, glyceryl monostearate, wax, mono-, di- and trisubstituted glycerides, calcium stearate and mixtures thereof.